Akeso Inc. has recently announced the completion of patient enrollment in its Phase III clinical trial for ivonescimab, a treatment for advanced biliary tract cancer $(BTC)$. This multicenter, randomized, controlled study is evaluating the combination of ivonescimab with standard therapy against durvalumab (PD-L1) combination therapy as a first-line treatment. The trial is being conducted in China and aims to assess the efficacy and safety of ivonescimab, which targets both PD-1 and VEGF, potentially offering synergistic anti-tumor effects. Results from this study have not yet been presented. Additionally, Akeso is pursuing a dual-path strategy for ivonescimab, focusing on domestic commercialization and global development, in partnership with Summit Therapeutics.